Irinotecan Kabi (Irinotecan Hydrochloride Trihydrate)

• Irinotecan Kabi is a topoisomerase I inhibitor used in colorectal cancer therapy.
• Metastatic colorectal cancer: improves survival when combined with fluoropyrimidine‑based regimens.
• Small cell lung cancer: provides benefit as second‑line therapy in combination with other agents.

• After intravenous administration, irinotecan is converted by hepatic carboxylesterases to the active metabolite SN‑38. SN‑38 binds to the DNA‑topoisomerase I complex, stabilizing it and preventing relegation of single‑strand DNA breaks, which ultimately blocks DNA replication and transcription, leading to tumor cell death.

Irinotecan Kabi may cause a range of adverse reactions.

Common Side Effects

• Neutropenia: decreased white blood cell count increasing infection risk.
• Diarrhea: often severe and may require antidiarrheal therapy.
• Nausea and vomiting: typical chemotherapy‑related symptoms.
• Alopecia: hair loss during treatment.
• Fatigue: generalized tiredness.
• Anemia: reduced red blood cell levels.

Serious or Rare Side Effects

• Febrile neutropenia: fever with low neutrophils, requiring urgent care.
• Severe colitis: life‑threatening inflammation of the colon.
• Hepatic toxicity: elevated liver enzymes or jaundice.
• Hypersensitivity reactions: rash, bronchospasm, or anaphylaxis.
• Pulmonary toxicity: interstitial pneumonitis or fibrosis.
• Hemorrhagic events: bleeding due to thrombocytopenia.

• Use of Irinotecan Kabi requires careful monitoring and patient assessment.
• Dose adjustment in renal impairment: reduce dose based on renal function.
• Monitor blood counts: perform regular CBC to detect neutropenia.
• Assess liver function: adjust for hepatic impairment.
• Avoid in patients with known hypersensitivity to irinotecan or its components.
• Pregnancy and lactation: use only if benefits outweigh risks; limited data.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Irinotecan Kabi can interact with several drug classes, necessitating vigilance.

Major Interactions (Avoid)

• Concurrent use with strong CYP3A4 inhibitors (e.g., ketoconazole) may increase toxicity.
• Co‑administration with UGT1A1 inhibitors (e.g., atazanavir) can raise SN‑38 levels.
• Combination with other myelosuppressive agents may cause severe bone marrow suppression.

Moderate Interactions (Monitor Closely)

• Concurrent use with anticoagulants may increase bleeding risk.
• Use with other antidiarrheal agents may mask symptoms.
• Combination with drugs affecting electrolyte balance may require monitoring.